Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

Literature DB >> 9593165

Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

Abstract

Activities of clinafloxacin, ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, ceftazidime, and imipenem against 354 ciprofloxacin-susceptible and -intermediate-resistant organisms were tested by agar dilution. Clinafloxacin yielded the lowest quinolone MICs (< or = 0.5 microg/ml against ciprofloxacin-susceptible organisms and < or = 16.0 microg/ml against ciprofloxacin-intermediate-resistant organisms) compared to those of levofloxacin, trovafloxacin, and sparfloxacin. Ceftazidime, piperacillin alone or combined with tazobactam, trimethoprim-sulfamethoxazole, and imipenem usually yielded higher MICs against ciprofloxacin-resistant strains.

Entities: Chemical

Mesh：

Substances：

Year: 1998 PMID： 9593165 PMCID： PMC105800 DOI： 10.1128/AAC.42.5.1269

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

22 in total

1. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors: P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal: Antimicrob Agents Chemother Date: 1991-04 Impact factor: 5.191

2. Trimethoprim-sulfamethoxazole.

Authors: W T Hughes
Journal: Pediatr Clin North Am Date: 1983-02 Impact factor: 3.278

3. In vitro activity of the new fluoroquinolone CP-99,219.

Authors: H C Neu; N X Chin
Journal: Antimicrob Agents Chemother Date: 1994-11 Impact factor: 5.191

4. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391.

Authors: M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; C L Heifetz
Journal: Diagn Microbiol Infect Dis Date: 1991 May-Jun Impact factor: 2.803

5. The in-vitro activity of PD127,391, a new quinolone.

Authors: A King; C Boothman; I Phillips
Journal: J Antimicrob Chemother Date: 1988-08 Impact factor: 5.790

6. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.

Authors: A S Ford; A L Baltch; R P Smith; W Ritz
Journal: J Antimicrob Chemother Date: 1993-04 Impact factor: 5.790

7. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.

Authors: A G Miranda; A R Wanger; K V Singh; B E Murray
Journal: Antimicrob Agents Chemother Date: 1992-06 Impact factor: 5.191

8. Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.

Authors: S R Norrby; M Jonsson
Journal: Antimicrob Agents Chemother Date: 1988-08 Impact factor: 5.191

9. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors: K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal: Antimicrob Agents Chemother Date: 1992-04 Impact factor: 5.191

10. The in-vitro activity of ceftazidime compared with that of other cephalosporins.

Authors: A J Bint; P Yeoman; P Kilburn; R Anderson; E Stansfield
Journal: J Antimicrob Chemother Date: 1981-09 Impact factor: 5.790

11 in total

1. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors: C L Clark; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1999-09 Impact factor: 5.191

Review 2. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors: C E Nord
Journal: Infection Date: 1999 May-Jun Impact factor: 3.553

3. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors: M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal: Antimicrob Agents Chemother Date: 2000-02 Impact factor: 5.191

4. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors: E A Coyle; G W Kaatz; M J Rybak
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

5. Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors: G M Eliopoulos
Journal: Drugs Date: 1999 Impact factor: 9.546

6. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors: K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2000-10 Impact factor: 5.191

7. Ciprofloxacin-resistant Escherichia coli in hospital wastewater of Bangladesh and prediction of its mechanism of resistance.

Authors: Farhima Akter; M Ruhul Amin; Khan Tanjid Osman; M Nural Anwar; M Manjurul Karim; M Anwar Hossain
Journal: World J Microbiol Biotechnol Date: 2011-09-09 Impact factor: 3.312

8. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors: H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191

9. Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.

Authors: B Frame; J Koup; R Miller; R Lalonde
Journal: Clin Pharmacokinet Date: 2001 Impact factor: 6.447

10. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.

Authors: J S Solomkin; S E Wilson; N V Christou; O D Rotstein; E P Dellinger; R S Bennion; R Pak; K Tack
Journal: Ann Surg Date: 2001-01 Impact factor: 12.969